Realcan Pharma Faces Huge Losses: Why Its Negative P/E Is Alarming Investors
Realcan Pharmaceutical’s 2025 stock shows a high‑to‑low range but a crushing –1070 P/E ratio, raising red flags about profitability and the future of a key health‑care distributor.
2 minutes to read
